华夏恒生生物科技ETF发起式联接(QDII)C(016971)利润分配表
| |
2026-06-30 |
2025-12-31 |
2025-06-30 |
2024-12-31 |
| 收入 |
-284,644,564.97 |
232,504,376.35 |
287,673,915.49 |
-59,434,006.11 |
| 利息合计 |
169,105.86 |
292,964.53 |
148,827.93 |
221,668.84 |
| 其中:存款利息收入 |
169,105.86 |
292,964.53 |
148,827.93 |
221,668.84 |
| 债券利息收入 |
- |
- |
- |
- |
| 资产支持证券利息收入 |
- |
- |
- |
- |
| 买入返售金融资产收入 |
- |
- |
- |
- |
| 投资收益合计 |
-40,716,766.18 |
234,076,007.01 |
58,870,088.53 |
-57,940,386.47 |
| 其中:股票投资收益 |
5,767,677.98 |
-242,245.53 |
-242,245.53 |
-1,086,998.25 |
| 基金投资收益 |
-39,543,664.65 |
233,991,784.34 |
59,064,958.71 |
-56,863,621.97 |
| 债券投资收益 |
373,333.79 |
326,468.20 |
47,375.35 |
10,233.75 |
| 资产支持证券投资收益 |
- |
- |
- |
- |
| 衍生工具收益 |
-7,314,113.30 |
- |
- |
- |
| 股利收益 |
- |
- |
- |
- |
| 基金分红收益收益 |
- |
- |
- |
- |
| 公允价值变动收益 |
-246,304,987.29 |
-5,261,258.07 |
227,203,789.46 |
-2,190,365.61 |
| 其他收入 |
2,419,382.94 |
3,393,727.39 |
1,451,209.57 |
475,077.13 |
| 费用 |
2,875,698.20 |
4,238,481.80 |
1,238,433.05 |
1,392,516.99 |
| 管理人报酬 |
320,835.86 |
316,345.08 |
95,187.61 |
127,654.26 |
| 基金托管费 |
96,250.71 |
94,903.54 |
28,556.26 |
38,296.33 |
| 销售服务费 |
2,255,113.14 |
2,773,209.29 |
804,696.73 |
1,054,378.01 |
| 交易费用 |
- |
- |
- |
- |
| 利息支出 |
- |
- |
- |
- |
| 其中:卖出回购金融资产支出 |
- |
- |
- |
- |
| 其他费用 |
106,447.11 |
211,093.46 |
97,171.11 |
172,188.39 |
| 利润总额 |
-287,520,263.17 |
228,265,894.55 |
286,435,482.44 |
-60,826,523.10 |